To evaluate the baseline impact of episode type ( manic vs. mixed ) , defined using DSM-IV-TR criteria , in bipolar I disorder ( BD-I ) on health-related quality of life ( HRQoL ) , and to investigate the differential effect of asenapine vs. placebo and olanzapine on HRQoL in BD-I patients with mixed episodes .